Vaderis Therapeutics develops targeted therapies for rare vascular diseases, including engasertib for hereditary haemorrhagic telangiectasia. The Basel biotech raised USD 152 million in a Series B co-led by Goldman Sachs Alternatives and TCGX, to fund its phase 3 study through to a possible US approval.
- Announced on
- Round
- Series B
- Amount
- USD 152 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- Goldman Sachs Alternatives lead
- TCGX lead
- Omega Funds
- EQT Life Sciences
- Perceptive Advisors
- Kalehua Capital
- Medicxi
- Droia
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic